We studied the hemodynamic effects of a 20% exchange transfusion with whole blood or highly purified human hemoglobin Ao. We compared the effects of unmodified hemoglobin with o-raffinose crosslinked oligomers of hemoglobin (modified hemoglobin). The unmodified SFH increased systemic vascular resistance (SVR) by -40%, and renal vascular resistance (RVR) by -25%. Cardiac output was markedly reduced (by -20%) and mean arterial pressure (MAP) only modestly increased (by -13%). In contrast, the modified hemoglobin solution caused less increase in SVR (-14%) and did not alter renal hemodynamics or blood pressure. We also compared the ability of the unmodified and crosslinked hemoglobins to inactivate nitric oxide (NO) in vitro using three separate assays; platelet NO release, NO-stimulated platelet cGMP production and EDRF-mediated inhibition of platelet aggregation. The unmodified hemoglobin inactivated NO to a markedly greater extent than the o-raffinose crosslinked hemoglobin in all three assays.
INTRODUCTION
Hemoglobin-based oxygen carrying solutions (HBOC's) have a number of potential advantages as blood substitutes. They can be produced in large volumes, stored for prolonged periods and administered rapidly, without need for typing and crossmatching.
These solutions can also be sterilized by pasteurization, reducing the risk of contamination by viruses and other infectious agents (1) (2) (3) (4) . A major challenge to the development of a safe red cell-free hemoglobin-based oxygen carrier has been the well recognized nephrotoxicity of crude hemolysate (5) (6) (7) (8) . However, three fundamental observations, made during the past few decades, have markedly reduced the toxicity and increased the efficacy of hemoglobin solutions (8) .
First, in 1967, Rabiner et al (9) demonstrated that the presence of red blood cell membrane fragments (red cell "stroma") contribute substantially to the toxicity and procoagulant activity of crude red cell hemolysates. This observation spurred the development of effective techniques to purify hemoglobin, a process that reduced, but did not eliminate, the toxicity of hemoglobin solutions (10) . Highly purified solutions of hemoglobin (which have become known as "stroma free" hemoglobin (SFH) solutions) can now be prepared in large volumes (2) .
A second important innovation was that hemoglobin molecules can be chemically modified to prevent the excretion of hemoglobin in the urine. Native hemoglobin (~64,500kD), when released from red cells, dissociates into dimers (~32,250kD) that are readily filtered at the glomerulus (11) . The presence of hemoglobin within the tubular lumen contributes substantially to hemoglobin-associated nephrotoxicity by causing intratubular obstruction and oxidant injury to renal epithelial cells. (5) (6) (7) (12) (13) (14) . Chemical crosslinking of dimers into tetramers and/or oligomers is one effective form of modification that reduces the ability of hemoglobin to cross the glomerular basement membrane and gain access to the renal tubules and substantially reduces nephrotoxicity (1) (2) (3) 8 ). An added advantage of chemical modification is that it prolongs the half-life of the hemoglobin in the circulation by preventing elimination in the urine and by slowing the rate of diffusion of hemoglobin from the circulation into the interstitial space (1) (2) (3) 8) .
A third discovery, essential for the efficacy of SFH solutions as effective oxygen carriers, was the use of chemical modification to optimize the oxygen affinity of SFH. Within the human red cell, the presence of 2,3,diphosphoglycerate (2,3-DPG) normally maintains the normal affinity of human hemoglobin for oxygen. Red cell-free hemoglobin loses this interaction with 2,3 DPG so that unmodified human SFH solutions have a very high oxygen affinity. Benesch and Benesch (15) were the first to demonstrate that chemical modification methods can also be used to reduce the oxygen affinity of the SFH for oxygen, resulting in an oxygen carrier that will effectively release oxygen at the physiologic pG*2 present in tissues.
However, despite the development of increasingly efficient and effective ways of removing red cell stroma and of cross-linking hemoglobin, many SFH solutions have continued to exhibit vasoconstrictor activity with resultant hypertension and reduced blood flow to various organs, including the heart, lung and kidney (8, 10, (16) (17) (18) . There is substantial evidence that these vasoactive properties of purified and modified SFH solutions are due, at least in part, to the well established ability of hemoglobin to bind and inactivate nitric oxide (NO) (19) (20) (21) (22) (23) .
This study was designed to evaluate systemic and renal hemodynamic effects of a highly purified hemoglobin solution that has been chemically crosslinked with o-raffinose to form oligomers of hemoglobin with a weight-average molecular weight of 230,000 (24) .
We have directly compared the hemodynamic effects of modified o-raffinose crosslinked hemoglobin with the highly purifed unmodified human hemoglobin Ao from which the crosslinked hemoglobin was made. We demonstrated that the unmodified SFH causes a severe increase in systemic vascular resistance and intrarenal vasoconstriction, and markedly reduces both cardiac output as well as renal function. In striking contrast, the o-raffinose crosslinked hemoglobin has no deleterious effect on cardiac function, glomerular filtration rate (GFR), or renal vascular resistance, and only modestly increases systemic vascular resistance. We also provide in vitro evidence that the effects of o-raffinose crosslinking on vasoactivity is associated with differences in the degree to which the modified and unmodified forms of the SFH solutions inactivate nitric oxide (NO).
METHODS

A. Reagents
Human serum albumin, sodium nitrite, trichloroacetic acid, trypan blue, Sepharose 2B, adenosine 5'-diphosphate (ADP), glutathione (GSH) and N(D-nitro-L-arginine methyl ester (L-NAME) were purchased from Sigma Chemical Co. (St. Louis, MO). Microcarrier beads (Cytodex 3) were obtained from Pharmacia, Uppsala, Sweden. Cyclic GMP enzyme immunoassay kits were purchased from Cayman Chemical Co. (Ann Arbor, MI). Inactin (thiobarbital sodium) was purchased from Research Biochemicals International (RBI) (Natick, MA).
B. Resuscitation solutions used for exchange transfusion
In animals exchanged with whole blood, the blood removed during the exchange was anticoagulated with heparin and administered back to the same animal. Human serum albumin (6g/dL) in Ringer's lactate was used as a non-hemoglobin-containing colloid solution. Human purified stroma-free hemoglobin (SFH) solutions were provided by Hemosol, Inc. (Toronto, Canada). All hemoglobin solutions were prepared in Ringer's lactate solution.
1) Methods used to produce the SFH solutions a) Unmodified human hemoglobin Ao (HbAo): Outdated human red cells are pooled, washed to remove plasma proteins, and lysed by gentle osmotic shock to minimize release of stromal components. The crude hemoglobin is separated from red cell ghosts by membrane microfiltration. The hemoglobin is converted to carbonmonoxyhemoglobin, and pasteurized for 10 hours at 62°C. Further purification is achieved using both anion-and cation-exchange chromatography to remove basic and acidic protein contaminants and to further reduce lipid and encapsulated virus contamination. A proprietary self displacement chromatography process, developed by Hemosol Inc., is used to prepare large volumes of purified HbAo. (25) . The purity of the HbAo, confirmed by several methods, is greater than 99%. No red cell membrane proteins are detectable. The combined phosphatidylethanolamine and phosphatidylinositol content of purified HbAo is <2jig/g hemoglobin (25, 26) b) SFH solutions crosslinked with o-raffinose i) o-raffinose crosslinked SFH solution #1 (Hemolink™): The deoxygenated HbAo is crosslinked through oxidation of the trisaccharide raffinose (25, 27) .
The aldehydes initially form imine, or Schiff base linkages with amino groups within and between individual hemoglobin molecules. These reversible bonds are then stabilized by chemical reduction using dimethylamino borane (28) . This reductive alkylation is irreversible and covalently crosslinks the two aß dimers between amino groups within the 2,3-DPG binding pocket to form stable tetramers. In addition o-raffinose reacts with surface amino groups of these tetramers to create intermolecular linkages producing a stabilized oligomeric hemoglobin with a weight-average molecular weight of 230,000
(ranging from 128,000 to 500,000). Methemoglobin is also reduced (from Fe 3+ to Fe 2+ ) during this treatment. Unreacted aldehydes are simultaneously reduced to alcohols to prevent further crosslinking. Excess reagents and byproducts are removed by diafiltration and the final solution formulated in the oxygenated state, in Ringer's lactate (USP) for injection (24) .
The o-raffinose solution #1 consists predominantly of a polymeric form of hemoglobin with a weight-averaged molecular weight of approximately 230,000 (Table I) . However, a substantial proportion of hemoglobin is in the tetrameric, 64Kd form (31.8%) and a small proportion of unmodified dimers of hemoglobin (32Kd) remains following diaflitration (Table I) .
ii) o-Raffinose crosslinked SFH solution #2: In order to determine the extent to which the residual dimeric (32kD) hemoglobin affected the hemodynamic effects of the modified SFH, o-raffinose crosslinked hemoglobin was processed to remove most of the remaining dimeric hemoglobin, leaving only 0.6% of hemoglobin in the dimerized form. This solution, called o-raffinose SFH solution #2 still contained substantial amounts (18.1%) of tetrameric hemoglobin ( 2. The characteristics of the resuscitation fluids.
The proportion of hemoglobin in the oligomeric, tetrameric and dimeric forms in the different o-raffinose SFH solutions is shown in Table I . The methods used to determine the proportion of different the molecular weight species of hemoglobin in the o-raffinose SFH solutions are described elsewhere (25) .
The human serum albumin (HSA), unmodified (Ao) SFH, and the three o-raffinose crosslinked solutions of SFH all had a comparable oncotic pressure of 20-24mmHg (Table   II) . Oncotic pressures were determined using a Wescor oncometer (Model 4400).
The proportion of hemoglobin in the form of methemoglobin was comparable in all SFH solutions (4-5%) (Table II) Hemoxanalyser (29)) of the unmodifed hemoglobin was very low (14.6mmHg) ( Table II) .
The crosslinking procedure substantially reduced the oxygen affinity of all o-raffinose solutions to a comparable extent (p50 values ~44mmHg) (Table II) .
C. In vivo rat protocols: GFR and PAH clearances were calculated using standard formulae. Renal plasma flow (RPF) was calculated from the clearance of PAH assuming a PAH extraction of 80% (31).
RBF was calculated as RPF/(1 -hematocrit). The FF is the fraction of plasma flow filtered at the glomerulus ((GFR/RPF)X100)). SVR was calculated by dividing MAP by CO. RVR was calculated by dividing MAP by RBF. FeNa and FeK were calculated by determining the concentration ratios of urine:plasma for Na and K and then by dividing these ratios by the concentration ratio of urine:plasma for inulin.
Exchange transfusion protocol.
The rats were subjected to a 20% exchange transfusion by removing 4 ml whole blood/300 g body weight from a femoral artery over 15 minutes. Then animals were divided into separate groups to receive 4 ml/300 g body weight of six different resuscitation fluids via a jugular venous line over a 10 minute period. The six solutions administered were: 1)
whole blood (n= 16); 2) Human serum albumin (HSA) 6g/dL in Ringer's lactate; 3)
and 6) o-Raffinose SFH #3 (n=10)( Table I) A separate group of rats (n=5) were subjected to sham surgery. These rats were anesthetized and exposed to the same operative maneuvers as the other rats except that no blood was removed and no resuscitative fluid was administered. After an equilibration period of 30 minutes, four 20-minute clearance periods were obtained in all groups for measurement of MAP, CO, heart rate (HR), GFR, and renal plasma flow (RPF). Renal blood flow (RBF), renal vascular resistance (RVR), systemic vascular resistance (SVR), fractional sodium excretion (FeNa) and fractional potassium excretion (FeK) were calculated as described above.
3. Experimental protocols to compare plasma levels and urine excretion of unmodified and modified SFH solutions.
In separate groups of animals, we determined the plasma levels and urine excretion rates of Ao SFH and o-raffinose SFH #1. Two groups of rats were exchange transfused with either Ao SFH (n=4) or o-raffinose SFH solution #1 (n=5) using the same methods described above. Heparanized blood was obtained by heart puncture 10 minutes after infusion. The blood was centrifuged and the plasma frozen at -70°C for measurement of 1 1 hemoglobin levels. Two separate groups of rats were also exchange-transfused with either Ao SFH (n=8) or o-raffinose SFH #1 (n=5), and urine was collected for 110 minutes starting immediately after completion of the infusion of SFH. At the end of the urine collection, heparinized blood was obtained by heart puncture for hemoglobin measurement. The volume of urine excreted over the 110 minutes was measured and the urine frozen for measurement of hemoglobin levels. Total free hemoglobin in plasma and urine was measured using a dual beam spectrophotometric assay as previously described (32) . Using this assay the lowest level of detection of hemoglobin is 1 mg/dl.
D. In vitro assays of hemoglobin-nitric oxide (NO) interactions
1) Preparation of the EDRF congener S-nitrosoglutathione (SNO-GSH)
SNO-GSH was prepared by reacting freshly prepared solutions of GSH with sodium nitrite at acidic pH, as previously described (33, 34) . SNO-GSH was prepared within 10 minutes of use, kept at 4°C, and diluted as necessary into aqueous buffer immediately before addition to assay systems.
2) Preparation of platelet-rich plasma (PRP)
Peripheral blood was drawn from healthy adult human volunteers who had not consumed acetylsalicylic acid or any other platelet inhibitor for at least seven days. The first 2 mL of blood drawn were discarded. Blood was then drawn into a sodium citrate anticoagulant. The citrated blood was centrifuged (150 x g, 15 minutes, 22°C) and the supernatant (PRP) was removed for further processing.
3) Preparation of Gel-Filtered Platelets
Gel-filtered platelets (GFP) were obtained by passing PRP over a Sepharose-2B column in
Tyrode's-Hepes buffered saline. Tyrode's-Hepes-buffered saline (HBS) consisted of 140 mM NaCl, 6 mM N-[2-hydroxyethyl]-piperazine-N-[2-ethane-sulfonic acid], 2 mM Na2HPC>4, 2 mM MgSC>4, 0.1% dextrose, and 0.4% BSA (pH 7.4,). Platelet counts were determined using a Coulter Counter, model ZM (Coulter Electronics, Hialeah, FL). Platelets were adjusted to 1.5x10^ platelets/ml by the addition of Tyrode's-Hepes-buffered saline.
4) Measurement of platelet aggregation
Aggregation of GFP (0.2 ml) was monitored using a standard nephelometric technique in which changes in light transmittance are recorded as a function of time (35) .
Aggregations were induced by adding 5 uM ADP, and the absolute change of light transmittance was recorded in a four-chamber aggregometer (BioData, Hatboro, Pennsylvania). GFP were incubated for one minute at 37°C with either i) S-nitrosoglutathione (SNO-GSH), ii) bovine endothelial cells on beads (ECBs), iii) SNO-GSH + SFH or iv) ECBs + SFH prior to the addition of ADP.
5) Measurement of platelet cyclic guanosine monophosphate fcGMP) production.
Trichloroacetic acid (final concentration, 5% vol/vol) was added to GFP. Samples were vortexed, placed on ice, and centrifuged at 1500xg for 10 minutes at 4°C. The supernatant was extracted with diethyl ether five times and assayed for cGMP by an enzyme-linked immunoadsorbent assay (ELISA) methodology using cGMP antiserum (Cayman Chemical
Co., Ann Arbor, MI).
6) Measurement of platelet NO production
We adapted a NO-selective micro-electrode (Inter Medical Co., Ltd. Nagoya, Japan) (36) for use in a standard platelet aggregometer (Payton Associates, Buffalo, NY) in order to monitor platelet NO production and aggregation simultaneously. The NO monitoring device consists of a headstage amplifier with a built-in power supply and two electrodes.
The working electrode (0.2 mm diameter, made from Pt/Ir alloy) and counterelectrode were inserted using a micro-manipulator into an aggregometer microcuvette containing a stir bar. The aggregometer, electrode, and headstage amplifier were housed in a Faraday cage to reduce electrical interference. The electrode current increased linearly from 10 to 350 pA over a range of NO concentrations. All experiments were conducted at constant temperature (37°C). Production of NO was determined by integrating the area under the response curve. Diethylamine NONOate was used to derive a standard curve which was linear over the range of 10-500 nM with a typical correlation coefficient of 0.95.
7) Determination of EDRF-induced inhibition of platelet aggregation a) Preparation of endothelial cell cultures on microcarrier beads (ECBs)
Bovine aortic endothelial cells were isolated and then grown in Dulbecco's modified Eagle's medium (DMEM) containing 10% fetal calf serum by established techniques (37) .
Cells were grown to confluence on a micocarrier system of collagen-coated spherical beads (Cytodex) as previously described (37) . The bovine endothelial cell-coated beads (ECBs)
were exposed to 30 pM acetylsalicylic acid for 1 h at 37°C to inhibit cyclooxygenase activity and prostanoid production, and then washed three times in HBS immediately before use.
Endothelial cells were checked for viability by trypan blue exclusion. ECBs were drawn up and permitted to settle in a packed volume of approximately 500 JJ.1 in a 1-ml Eppendorf pipette tip as previously described (37) . those of sham operated rats and rats exchange-transfused with whole blood (p<0.01)( Figure   1 ). The'hematocrit of the unmodified (Ao) SFH exchanged rats was higher than that of rats exchanged with albumin or the o-raffinose cross-linked SFH solutions (p<0.01).
2. Effects of exchange transfusion on systemic hemodynamics.
MAP in rats exchange transfused with unmodified hemoglobin (Ao) was increased by -15% compared to blood exchanged animals (P<0.01 vs blood group) (Table HI) . MAP in rats exchanged transfused with o-raffinose crosslinked SFH solution #1 was increased by ~10%(p<0.01 vs blood group) and comparable to the change in MAP induced by hemoglobin Ao (Table HI) . The MAP in rats exchanged-ransfused with o-raffinose crosslinked SFH solution #2 and o-raffinose crosslinked SFH solution #3 were not significantly different from MAP in whole blood exchanged animals (Table III) .
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The unmodified SFH markedly reduced cardiac output by -21% below that of rats exchanged with whole blood. In contrast, the cardiac outputs of rats exchanged with all the ox-raffinose solutions were comparable to the cardiac output meausred in blood-exchanged rats. The albumin solution increased cardiac output compared to blood exchanged animals by -30% (P<0.01)( Table JE) .
The albumin solution caused a fall in SVR below blood exchanged rats (Table HI) . The unmodified (Ao) SFH solution resulted in a marked (-46%) increase in SVR above that inanimals exchanged with whole blood (P<0.01) (Figure 2 , Table HI ). The o-raffinose crosslinked SFH solution #1 increased SVR to a substantially lesser extent than Ao SFH (by -15%) (P<0.01) ( Figure 2 , Table III ). The SVR in animals exchanged with o-raffinose crosslinked SFH solution #2 and o-raffinose crosslinked SFH solution #3 was -12% higher than SVR in blood exchanged rats, although this difference was not statistically significant (Table HI) . SVR was sustained during each of the four observational periods in rats exchanged with whole blood, Ao SFH or o-raffinose crosslinked SFH solution #2 ( Figure   2 ). -
Effects of exchange transfusion or sham surgery on renal function (GFR),
intrarenal hemodynamics and electrolyte excretion.
The unmodified hemoglobin Ao markedly reduced GFR and renal blood flow below that of animals exhanged with whole blood, albumin, and o-raffinose crosslinked SFH solutions (p<0.01) (Table IE) . Calculated RVR was reduced in albumin exchanged rats below blood exchanged rats. RVR was markedly increased (almost two fold) in Ao hemoglobin exchanged rats compared to RVR in whole blood exchanged animals. The RVR in all three O-raffinose exchanged rats was not different from blood exchanged animals.
Fractional excretion of sodium (FeNa) and potassium (FeK) was higher in animals exchanged with albumin, unmodifed SFH and the o-raffinose crosslinked SFH solutions compared to blood exchanged animals (p<0.01)( Table V) .
Plasma and urine hemoglobin levels.
Both the Ao SFH and the o-raffinose crosslinked SFH solution #1 reached comparable concentrations in plasma when measured 10 minutes after exchange transfusion (Table   VI ). The concentration of both SFH solutions fell over the the 110 minute period of observation but the plasma level of the unmodified SFH fell to a far greater extent than that of the o-raffinose crosslinked SFH (Table VI) . A substantial amount of the unmodified hemoglobin Ao was excreted in the urine (282+0.lug/min). The total amount of unmodofied SFH eliminated by the kidney represents at least 35% of the administered load. In contrast, in rats given o-raffinose crosslinked SFH, no hemoglobin was detectable in the urine.
B. Interactions between the hemoglobin solutions and nitric oxide in vitro.
Effect of hemoglobins on platelet release of NO.
Platelets activated with 5uM ADP produce NO, which diffuses from the platelets and inhibits the recruitment of additional platelets to the growing platelet thrombus (38) . We have adapted a microelectrode methodology to measure platelet NO production in real time during the platelet aggregation response. NO bound by hemoglobin is not detected by this method.
Gel-filtered platelet aggregation was induced with 5(i.M ADP in the absence or presence of l(iM heme in the form of unmodified SFH or o-raffinose crosslinked SFH solutions #1, #2
or #3. As shown in Table VII , the unmodified hemoglobin inhibited NO released by aggregating platelets almost completely (by -99%). The o-raffinose crosslinked SFH solutions also reduced NO release, but did so to a far lesser extent than the unmodified SFH (by -80%). NO release in the presence of the three o-raffinose crosslinked SFH solutions was comparable (Table VII) .
Effect of SFH solutions on platelet cGMP production induced by SNO-GSH.
Gel-filtered platelets were incubated with 10 |iM SNO-Glu for 5 minutes. Platelet proteins were then precipitated with trichloroacetic acid and cGMP content determined in the supernatant. Unmodified SFH markedly suppressed platelet cGMP below control values (Table VTfl) . In contrast, all O-raffinose cross-linked SFH solutions had only a modest effect on cGMP production which was not statistically different from control values (Table VHI) .
Effect of hemoglobin solutions on EDRF inhibition of platelet aggregation.
Bovine aortic endothelial cells (BAECs) grown on Cytodex beads (ECBs) were incubated with or without ljiM unmodified or o-raffinose crosslinked SFH solutions for 5 minutes.
Then, GFP was added and the suspension stirred in an aggregometer for 5 minutes. The
ECBs were allowed to settle, the GFP removed, and aggregation induced with 5uM ADP. As shown in Figure 3 , unmodified SFH reversed the inhibition of platelet aggregation by EDRF released from ECBs with the extent of aggregation increasing 223+43% above control ( Figure 3 ). In contrast, the o-raffinose crosslinked SFH solutions had a far more modest effect on EDRF inhibition of platelet aggregation, increasing the extent of aggregation by only 30-60%. There was no significant difference among the three o-raffinose crosslinked SFH solutions (Figure 3 ).
DISCUSSION
Many different preparations of SFH have been developed and evaluated by a diverse array of research groups in academic centers, private companies as well as the military (1, 3, 8) .
While all of these SFH solutions are subjected to purification techniques with removal of most of the non-hemoglobin contaminants, the method and efficacy of purification differs substantially amongst SFH solutions. The presence of some non-hemoglobin contaminants are thought to contribute to the vasoactive effects of some of these products (16) . At present there is still some uncertainty regarding the extent to which the hemoglobin molecule itself contributes to the toxicity of SFH solutions (2, 8, 39 ).
The major purpose of this study was to examine the influence of one available method of chemical crosslinking on the vasoactivity of the hemoglobin molecule itself. This represents the first study in which the hemodynamic and renal effects of a modified SFH solution and its unmodified precursor are directly compared. We compared the effects of o-raffinose crosslinked hemoglobin and unmodified, highly pure SFH Ao which was used to make the crosslinked SFH. Since both unmodified and modified solutions are of comparable purity (25) , any differences in cardiac, renal, or vascular effects cannot be ascribed to differences in the concentration of non-hemoglobin contaminants.
The hematocrit of rats exchange transfused with whole blood was the same as sham operated rats (Figure 1 ). The hematocrit was reduced to the same degree in rats exchanged with HS A and each of the three o-raffinose crosslinked solutions (Figure 1 ). However, while the hematocrit was markedly reduced in rats exchanged with the unmodified SFH, it was significantly higher than in the groups exchanged with HSA and all the o-raffinose crosslinked SFH solutions (Figure 1 ). Since the unmodified SFH is rapidly cleared from the plasma (Table VI) , the loss of the colloid from the circulation likely leads to diffusion of plasma water from the vascular bed with resultant increase in the hematocrit. It is also possible that the intense vasoconstriction induced by the unmodified SFH increases the filtration of plasma water into the interstitial space as a result of altered Starling's forces.
We demonstrated marked differences in the systemic and intrarenal effects betrween modified and unmodified hemoglobin solutions. The unmodified hemoglobin (SFH Ao) results in a marked elevation in systemic vascular resistance (SVR) of -45% when compared to the effects of exchange with whole blood (Table III) . MAP is also increased by Ao SFH but, by comparison with the change in SVR, this increase is relatively modest (by -14%)( Table IE) . The marked proportional difference in the severity of the increase in MAP and SVR is accounted for by the profound depressant effect of Ao SFH on cardie output (Table III) . We have not examined the extent to which the reduction in cardiac output induced by Ao SFH is the possible result of myocardial ischemia (due to vasoconstriction of the coronary vasculature) and /or direct suppression of myocardial contractility. Ao SFH also induced marked constriction of the renal vasulature with resultant reduction in both GFR and RBF (Table IV) .
While the o-raffinose crosslinked SFH solution #1 also increases SVR, this effect is relatively modest and substantially less than the increase in SVR induced by the Ao SFH (Table III) . In addition, o-raffinose crosslinked SFH solution #1 has no deleterious effect on cardiac output so that the increase in MAP induced by o-raffinose crosslinked SFH solution #1 is proportionately comparable to the modest increase in SVR induced by this modified SFH solution. Also, unlike the unmodified SFH Ao, o-raffinose crosslinke SFH solution #1 has no effect on the GFR, renal blood flow, or RVR when compared to rats exchanged with whole blood (Table III and PV) . Thus, our data demonstrate that the process of oraffinose crosslinking markedly alters the vasoactive properties of the hemoglobin molecule itself. Adverse effects on MAP and SVR are markedly attenuated and reductions in cardiac and renal function completely eliminated.
All SFH solutions as well as the HSA (unmodified as well as modified) increased the fractional excretion of sodium (FeNa) and potassium (FeK) when compared to whole blood-exchanged rats and to a comparable extent (Table V) . The cause of this increase in fractional electrolyte excretion is probably multifactorial, but compared to rats receiving whole blood, those given either SFH solutions or HSA received about twice the volume of red-cell free electrolyte solution. This augmented water and electrolyte load likely contributed to the diuresis, natriuresis and kaliuresis associated with all these solutions.
We also examined the extent to which the modest effects of the o-raffinose cross-linked SFH solution #1 on SVR and MAP are due to the presence of some smaller molecular weight moieties (dimers and tetramers) of hemoglobin in this solution. We compared the effects of o-raffinose SFH in which the concentration of the dimeric hemoglobin (oraffinose crosslinked SFH solution #2) or dimeric as well as tetrameric hemoglobin (oraffinose crosslinked SFH solution #3) was substantially reduced (Table I ). The effects of these solutions on MAP, cardiac output, SVR, RVR and GFR are not different from those of the o-raffinose crosslinked SFH solution #1. Thus, efforts to remove the smaller molecular weight hemoglobin molecules present in the o-raffinose crosslinked SFH solution #1 provided no substantive benefit in systemic or renal hemodynamics.
We have also found that the retention time of the unmodified SFH Ao in the circulation is extremely short. The rapid fall in plasma levels after infusion of Ao SFH (Table VI) is likely due to rapid leakage out of the vascular space into interstitial fluid as well as to excretion in the urine. The increased plasma retention time of the polymerized solution and the absence of appearance of the modified hemoglobin in the urine is likely due to the increased size of oligomerized hemoglobin, which prevents loss of hemoglobin in the urine and slows passage of the hemoglobin across capillary walls.
We did additional studies to investigate the mechanism/s responsible for the striking reduction in vasoactivity associated with o-raffinose crosslinked SFH. One mechanism by which the hemoglobin molecule may potentially induce systemic and intrarenal vasoconstriction is by inactivating or binding nitric oxide (NO) (8) . The ability of hemoglobin to inhibit endothelium-dependent vasodilation (EDRF) was demonstrated (19) long before endothelial release of NO was shown to account for this activity (40) .
Subsequently, the interactions between hemoglobin and NO have been well characterised (20) (21) (22) 41) . The binding affinity of hemoglobin for NO is much higher than for either O2 or CO (20 Finally, some evidence suggests that NO can bind to sulfhydryl groups on the globin chain of hemoglobin (42) .
The constitutive production of endothelial-derived NO plays an important role in regulating normal vascular tone and blood pressure (43) . Thus, inhibition of NO activity by hemoglobin would be expected to cause systemic vasoconstriction and hypertension as well as intrarenal vasoconstriction and a reduction in GFR (17, (21) (22) (23) 43) .
In order to determine if the reduced vasoactivity of the o-raffinose crosslinked SFH solutions is related due to an alteration in the binding of NO, we compared the effects of the unmodified and o-raffinose crosslinked SFH solutions on NO activity in vitro . We used a number of different assay systems, including platelet NO production (Table VII) , platelet cGMP production (Table VIII) hemoglobin A substantially attenuates the cooperativity in its reactions with NO. Taken together, these observations suggest the possibility that cross-linking hemoglobin changes the conformation of the heme binding site, and enhances hydration rates, thereby decreasing reactivity toward NO.
In summary,unmodified SFH causes marked systemic and intrarenal vasoconstriction, and a profound reduction in both cardiac output and GFR. In marked contrast, the oraffinose crosslinked SFH solutions increase SVR only modestly and have no effect on cardiac output, GFR or renal hemodynamics. Since this is the first in vivo study that has compared unmodified and modified hemoglobins of identical purity, we are able to clearly establish that the hemoglobin molecule itself has vasoconstrictor properties that are independent of and likely additive to the effects of contamination by red cell stroma. We have also shown that one form of hemoglobin modification, (using o-raffinose to crosslink hemoglobin into oligomers), substantially ameliorates the vasoconstrictor effects and eliminates the adverse effects of unmodified hemoglobin of cardiac and renal function.
The mechanism responsible for these beneficial effects of cross-linking have not been directly examined in vivo. However, in vitro studies demonstrate that the cross-linked hemoglobin inactivates NO to a substantially lesser extent than unmodified hemoglobin.
On the basis of these findings we suggest that the differences in the hemodynamic effects of the unmodified and o-raffinose crosslinked SFH solutions is related, at least in part, to differences in the extent to which NO is inactivated by these two SFH solutions in vivo.
The development of an SFH solution with no acute nephrotoxic or cardiotoxic effects is an encouraging advance in the development of a therapeutically useful hemoglobin-based oxygen carrying solution. 
